Abstract
Treatment of varicella-zoster virus (VZV) infections must be based on multiple factors, including the patient’s immune status, age, and clinical presentation. Intravenous acyclovir therapy is the preferred treatment for VZV infections in immunocompromised hosts and those normal individuals with severe disease. Immunocompetent hosts with herpes zoster may be managed as outpatients with high doses of oral acyclovir. At present, topical therapy has no role in the treatment of VZV infections. Further studies with acyclovir and its derivatives, as well as several unrelated antiviral agents, may enable oral therapy of VZV infections in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
